Fervent Pharmaceuticals Completes Clinical Trial For Promising New Post-Menopausal Therapy Treating Vasomotor Symptoms

Wednesday, November 14, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

GREENVILLE, N.C., Nov. 14, 2018 /PRNewswire/ -- Fervent Pharmaceuticals of Greenville, N.C.

has successfully completed its Phase 2A clinical trial for FP-101, a new therapy developed to treat the vasomotor symptoms associated with menopause, like hot flashes and night sweats.

The two-month clinical trial included 112 women in

North Carolina, South Carolina, Illinois, and Tennessee. Fervent partnered with Winston-Salem-based PMG Research to recruit patients and conduct the trial.

"Completing this clinical trial brings us one step closer to achieving our mission, which is to better women's lives through new therapies for menopausal symptoms," George Royster, founder of Fervent Pharmaceuticals, said. "Night sweats and hot flashes interrupt the everyday lives of women, and we're addressing those symptoms through FP-101."

The therapy in trial is an orally dosed, non-hormonal, non-herbal, non-antidepressant formulation of a compound that has known mechanisms of action, is already FDA-approved for another undisclosed indication, and has a long history of safe use.

FP-101 demonstrated a 90% efficacy rate in its pilot study, and Fervent expects similar results to emerge from the clinical trial when the data has been fully analyzed.

Fervent is able to utilize the FDA's simpler application process for a new indication rather than the full application for a new compound. This expedited process, which uses prior research on the compound, will shorten application time and lower the costs associated with bringing FP-101 to market.

Fervent Pharmaceuticals is a clinical stage drug development company founded in North Carolina in 2011. It is focused on improving women's quality of life by developing therapies targeting unmet needs in women's health. Learn more at www.FerventPharma.com.

Cision View original content:http://www.prnewswire.com/news-releases/fervent-pharmaceuticals-completes-clinical-trial-for-promising-new-post-menopausal-therapy-treating-vasomotor-symptoms-300750520.html

SOURCE Fervent Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store